Are you ready to amplify your academic presence and connect with a global network of researchers? Join the Scholar Indexing Society and elevate your research to new heights!
Middle Meningeal Artery Embolization and Nonacute Subdural Hematoma
Article Number: SIS079482AI220525
22nd May, 2025
Author(s):
Peter Kan
Abstract:
Nonacute subdural hematoma (SDH) is a growing concern among aging populations, particularly with increased use of antiplatelet and anticoagulant therapies. Traditional treatments, including glucocorticoids, statins, and surgical evacuation, are associated with high recurrence rates (15%). Middle meningeal artery (MMA) embolization has emerged as a promising adjunct or standalone therapy to reduce recurrence by targeting the vascularized hematoma membrane. Recent randomized trials (EMBOLISE, MAGIC-MT, STEM) demonstrate its efficacy, with recurrence rates dropping to 5–10% when combined with surgery. However, outcomes vary based on timing (pre- vs. post-surgical embolization) and patient selection (e.g., coagulopathy or nonsurgical candidates). While MMA embolization shows potential, questions remain about its role as primary therapy, optimal embolic materials, and safety in special populations. Further trials are needed to refine its use in SDH management.